Zydus Cadila has received approval from the USFDA to market Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg. The drug falls in the anti-bacterials segment.
[adsense:336x280:8701650588]
With this first approval, the group will now commence supplies to the US market from its formulation manufacturing facility located at the SEZ in Ahmedabad.
[adsense:468x15:2204050025]
The group now has 102 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
